In Israel, hospitals received the right to appoint a cocktail from Regeneron antibodies to treat patients with coronavirus. In the afternoon, this drug has already received the first 17 patients, writes the Israeli edition vesty.co.il.
According to Regeneron studies prevents the difficult course of COVID-19 in patients with risk groups.
Edition has tried to figure out what kind of drug, to whom it is appointed, how it is introduced, what side effects are in.
Regeneron, which has the scientific name REGN-COV2, is a cocktail of two types of antibodies to coronavirus. It is administered intravenously to slow down the spread of the virus in the respiratory system and infection of the unreleased cells. It should be introduced at an early stage of the disease, during which antibodies can slow down the spread of the virus. Introduction at a too late stage is ineffective, since at this time the main role in defense belongs to T-lymphocytes destroying the viruses already penetrated into the cells. Studies have shown that Regeneron reduces the risk of transition of the disease in a heavy form by 70%.
Antibodies must identify coronavirus, neutralize it and mark it in order for it to be destroyed by leukocytes. Synthetic antibodies of the drug are replaced by antibodies that did not work out in the patient: they are injected into the bloodstream through the catheter, and they apply throughout the body.
When they face coronavirus, they neutralize it and prevent its penetration into unreleased cells. T-lymphocytes destroy viruses marked with antibodies.
The medicine is administered intravenously. The procedure is carried out by a doctor and sister arriving at home to the patient, or it is held in the hospital. After preparing the dropper, the patient is introduced into Vienna the Venflon catheter and through it for half an hour the drug enters the body. After that, doctors are watching the patients within an hour.
As for side effects, how any biological preparation, in rare cases, Regeneron can cause an allergic reaction, which is why monitored patients within an hour. But in general, the medicine has a high level of security.
The medicine is intended for patients with COVID-19 in light or moderate severity. In such patients there should be no significant respiratory symptoms, and they must belong to groups of increased risk on the transition of the disease in a heavy form and for mortality.
The drug can obtain people with a severe course of COVID-19, as well as patients with a significant tail required, requiring the dacha oxygen, or with saturation below 94%.
It is believed that this medicine prevents hospitalization in 85% of cases and mortality in 70% of cases. He has permission from the FDA, and he helped to recover former US president Donald Trump.